ArticlePersonalized medicine2009
MicroRNA polymorphisms: a giant leap towards personalized medicine.
Article in Personalized medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs' World.Cells · 2019Review
- Pattern recognition for predictive, preventive, and personalized medicine in cancer.The EPMA journal · 2017Review
- Down-expression of miR-152 lead to impaired anti-tumor effect of NK via upregulation of HLA-G.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis.Expert review of molecular diagnostics · 2014Article
- Integrated analysis of miRNA and mRNA during differentiation of human CD34+ cells delineates the regulatory roles of microRNA in hematopoiesis.Experimental hematology · 2014Article
- MicroRNAs as promising biomarkers in cancer diagnostics.Biomarker research · 2014Article
- The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins.Pharmacogenomics · 2012Article
- MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism.PloS one · 2009Article
- MicroRNA reexpression as differentiation therapy in cancer.The Journal of clinical investigation · 2009Article
- Perspectives on personalized cancer care.Urologic oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
"An individual's genetic inheritance of microRNA polymorphisms associated with disease progression, prognosis and treatment holds the key to create safer and more personalized drugs and can be a giant leap towards personalized medicine."
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.